

Variant: *m.13513G>A*

Version: 1.1

[CA120632](#)

[9702 \(ClinVar\)](#)

Gene: MT-ND5 ([HGNC:4540](#))

Condition: mitochondrial disease ([MONDO:0044970](#))

Inheritance Mode: Mitochondrial inheritance

UUID: 7dcf79c3-61e2-40bb-bb3a-06d45c7c2c23

Approved on: 2021-10-26

Published on: 2021-10-26

HGVS expressions

NC_012920.1:m.13513G>A

J01415.2:m.13513G>A

ENST00000361567.2:c.1177G>A

Pathogenic

Met criteria codes 5

PP3 **PM5** **PP1_Moderate**

PM6_Strong **PS4**

Evidence Links 0

Expert Panel

[Mitochondrial Diseases VCEP](#)

Criteria Specification Information !

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

Mitochondrial Diseases VCEP

The m.13513G>A (p. D393N) variant in MT-ND5 was reviewed by the Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel as part of the variant pilot for mitochondrial DNA variant specifications (McCormick et al., 2020; PMID: 32906214). This variant has been reported in >16 individuals with primary mitochondrial disease with onset typically in childhood with some reports of onset in adolescence who had features variably consistent with Leigh syndrome, MELAS and MELAS-like, and/or mitochondrial encephalopathy (PS4; PMID: 25681084; PMID: 27344355; PMID: 30128709; PMID: 12624137; PMID: 14520659; PMID: 17400793; PMID: 18495510). This variant has been identified as a de novo occurrence in at least 5 probands with primary mitochondrial disease (PM6_strong; PMID: 27344355; PMID: 17400793; PMID: 18495510). This variant heteroplasmy level segregated with severity in 6 families where healthy mothers were found to have the variant at low heteroplasmy levels (PP1_moderate; PMID: 25681084; PMID: 12624137; PMID: 14520659). Another variant at this amino acid position leading to a different amino acid change is classified as pathogenic by mitomap.org and ClinVar - m.13514A>G (p.D393G; PM5). The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.97 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). In summary, this variant meets criteria to be classified as pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD U24 Mitochondrial Disease Variant Curation Expert Panel as of August 20, 2020. Mitochondrial DNA-specific ACMG/AMP criteria applied: PS4, PM6_strong, PM5, PP1_moderate, PP3).

Met criteria codes

PP3	✓	APOGEE: 0.97 - pathogenic
PM5	✓	m.13514A>G (p.D393G) confirmed pathogenic in MITOMAP and ClinVar (one submission)
PP1_Moderate	✓	This variant heteroplasmy level segregated with severity in 6 families where healthy mothers were found to have the variant at low heteroplasmy levels (PP1_moderate; PMID: 25681084; PMID: 12624137; PMID: 14520659).
PM6_Strong	✓	This variant has been identified as a de novo occurrence in at least 5 probands with primary mitochondrial disease. Per SVI de novo guidance (Phenotype consistent with gene but not highly specific), total is 2.5 points (0.5 from Patient 1 in PMID: 18495510 + 0.5 from Patient 2 in PMID: 18495510 + 0.5 from Patient 3 in PMID: 17400793 + 0.5 from Patient 4 in PMID: 17400793 + 0.5 from case in PMID: 27344355)
PS4	✓	This variant has been reported in >16 individuals with primary mitochondrial disease with onset typically in childhood with some reports of onset in adolescence who had features variably consistent with Leigh syndrome, MELAS and MELAS-like, and/or mitochondrial encephalopathy (PS4; PMID: 25681084; PMID: 27344355; PMID: 30128709; PMID: 12624137; PMID: 14520659; PMID: 17400793; PMID: 18495510).

Curation History [↗](#)

	▼	▼
--	---	---

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.